HK1209725A1 - Bendamustine derivatives and related compounds, and medical use thereof cancer therapy - Google Patents
Bendamustine derivatives and related compounds, and medical use thereof cancer therapyInfo
- Publication number
- HK1209725A1 HK1209725A1 HK15110327.6A HK15110327A HK1209725A1 HK 1209725 A1 HK1209725 A1 HK 1209725A1 HK 15110327 A HK15110327 A HK 15110327A HK 1209725 A1 HK1209725 A1 HK 1209725A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer therapy
- related compounds
- medical use
- bendamustine
- bendamustine derivatives
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical class ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661374P | 2012-06-19 | 2012-06-19 | |
US201261670158P | 2012-07-11 | 2012-07-11 | |
PCT/EP2013/062347 WO2013189847A1 (en) | 2012-06-19 | 2013-06-14 | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209725A1 true HK1209725A1 (en) | 2016-04-08 |
Family
ID=48628661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110327.6A HK1209725A1 (en) | 2012-06-19 | 2015-10-21 | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy |
Country Status (13)
Country | Link |
---|---|
US (2) | US10526290B2 (xx) |
EP (1) | EP2861564B1 (xx) |
JP (1) | JP6153606B2 (xx) |
KR (1) | KR101955065B1 (xx) |
CN (1) | CN104395296A (xx) |
BR (1) | BR112014031556B1 (xx) |
CA (1) | CA2875455C (xx) |
ES (1) | ES2694757T3 (xx) |
HK (1) | HK1209725A1 (xx) |
MX (1) | MX365192B (xx) |
RU (1) | RU2695383C2 (xx) |
UA (1) | UA117809C2 (xx) |
WO (1) | WO2013189847A1 (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2890462A1 (en) | 2012-11-12 | 2014-05-15 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
EP2886536A1 (en) * | 2013-12-19 | 2015-06-24 | Helmut Schickaneder | Bendamustine derivatives as anti-proliferative agents |
WO2017162661A1 (en) | 2016-03-22 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | 1h-benzo[de]isoquinoline-1,3(2h)-diones |
CA3082375A1 (en) | 2017-11-13 | 2019-05-16 | Ecolab Usa Inc. | A novel one-pot homogeneous process for the large scale manufacture of 2-substituted benzimidazoles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD34727A1 (de) * | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
AU6859394A (en) * | 1993-05-25 | 1994-12-20 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JPWO2007029847A1 (ja) * | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
WO2010042568A1 (en) | 2008-10-08 | 2010-04-15 | Cephalon, Inc. | Processes for the preparation of bendamustine |
US20130217888A1 (en) * | 2010-11-01 | 2013-08-22 | Shailpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
PT2656843E (pt) * | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Ésteres de bendamustina e compostos relacionados e a sua utilização médica |
-
2013
- 2013-06-14 WO PCT/EP2013/062347 patent/WO2013189847A1/en active Application Filing
- 2013-06-14 UA UAA201413290A patent/UA117809C2/uk unknown
- 2013-06-14 BR BR112014031556-6A patent/BR112014031556B1/pt not_active IP Right Cessation
- 2013-06-14 ES ES13729324.7T patent/ES2694757T3/es active Active
- 2013-06-14 CA CA2875455A patent/CA2875455C/en not_active Expired - Fee Related
- 2013-06-14 CN CN201380031893.XA patent/CN104395296A/zh active Pending
- 2013-06-14 KR KR1020147035678A patent/KR101955065B1/ko active IP Right Grant
- 2013-06-14 US US14/405,996 patent/US10526290B2/en not_active Expired - Fee Related
- 2013-06-14 EP EP13729324.7A patent/EP2861564B1/en not_active Not-in-force
- 2013-06-14 RU RU2014146896A patent/RU2695383C2/ru active
- 2013-06-14 JP JP2015517698A patent/JP6153606B2/ja not_active Expired - Fee Related
- 2013-06-14 MX MX2014014895A patent/MX365192B/es active IP Right Grant
-
2015
- 2015-10-21 HK HK15110327.6A patent/HK1209725A1/xx not_active IP Right Cessation
-
2017
- 2017-07-11 US US15/647,257 patent/US10294208B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20150020581A (ko) | 2015-02-26 |
UA117809C2 (uk) | 2018-10-10 |
CN104395296A (zh) | 2015-03-04 |
JP6153606B2 (ja) | 2017-06-28 |
RU2695383C2 (ru) | 2019-07-23 |
RU2014146896A (ru) | 2016-08-10 |
US20150152066A1 (en) | 2015-06-04 |
JP2015520200A (ja) | 2015-07-16 |
BR112014031556A2 (pt) | 2015-12-22 |
EP2861564B1 (en) | 2018-08-08 |
ES2694757T3 (es) | 2018-12-27 |
US20170313663A1 (en) | 2017-11-02 |
MX2014014895A (es) | 2015-06-17 |
US10526290B2 (en) | 2020-01-07 |
BR112014031556B1 (pt) | 2019-10-29 |
KR101955065B1 (ko) | 2019-03-06 |
WO2013189847A1 (en) | 2013-12-27 |
EP2861564A1 (en) | 2015-04-22 |
US10294208B2 (en) | 2019-05-21 |
CA2875455C (en) | 2020-03-10 |
MX365192B (es) | 2019-05-23 |
CA2875455A1 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190046T1 (hr) | Kombinirana terapija za liječenje raka | |
IL238662A (en) | Bandostatin derivatives, containing them and used to treat cancer | |
IL231386A (en) | Pyrazolequinoline derivatives, their preparation and medical use | |
HK1192758A1 (zh) | '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物 | |
EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
EP3071280A4 (en) | TREATMENT CATHETER COMPRISING THE ADMINISTRATION OF THERAPEUTIC ENERGY | |
EP2537530A4 (en) | RADIOTHERAPY AGENT | |
EP2830633A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
EP2863983B8 (en) | Medical therapy arrangement | |
HK1207013A1 (en) | Catheter for photodynamic therapy | |
IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
HK1209725A1 (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy | |
LT2872176T (lt) | Karboranilporfirinai, skirti naudoti vėžio gydymui | |
GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
PL2656843T3 (pl) | Estry bendamustyny i związki pokrewne i ich medyczne zastosowanie | |
EP2934500A4 (en) | COMBINATION THERAPY AGAINST CANCER | |
HK1209127A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
HK1213475A1 (zh) | 用於癌症治療的 、卡培他濱和奧沙利鉑的組合 | |
EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
EP2905284A4 (en) | PHOTOSENSITIZATION TARGETING THYMIDINE KINASE AND PHARMACEUTICAL COMPOSITION AND USE FOR THE TREATMENT OF ASSOCIATED CANCER | |
IL233495A0 (en) | Combination for cancer treatment | |
IL239231A0 (en) | Combined cancer treatment | |
GB201222544D0 (en) | Photodynamic therapy and diagnosis | |
HUP1200530A2 (en) | Medical splint |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230608 |